APGE Stock Summary and Trading Ideas (Apogee Therapeutics | NASDAQ:APGE)

Apogee Therapeutics Inc is a clinical-stage biotechnology company engaged in advancing optimized, novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. . Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.

Apogee Therapeutics trades on the NASDAQ stock market under the symbol APGE.

As of August 10, 2026, APGE stock price declined to $134.65 with 735,277 million shares trading.

APGE has a beta of -0.98, meaning it tends to be less sensitive to market movements. APGE has a correlation of 0.04 to the broad based SPY ETF.

APGE has a market cap of $10.18 billion. This is considered a Large Cap stock.

In the last 3 years, APGE traded as high as $134.88 and as low as $14.19.

The top ETF exchange traded funds that APGE belongs to (by Net Assets): VTI, XBI, IWM, VB, VXF.

APGE has outperformed the market in the last year with a return of +274.0%, while the SPY ETF gained +23.5%. In the last 3 month period, APGE beat the market returning +64.6%, while SPY returned +5.9%. However, in the most recent 2 weeks APGE has underperformed the stock market by returning +0.3%, while SPY returned +4.6%.

APGE support price is $134.67 and resistance is $135.01 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that APGE shares will trade within this expected range on the day.